e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS
Tangram Therapeutics (OTC:ETXPF), formerly e-therapeutics, has announced a strategic corporate relaunch and unveiled its next-generation AI platform, LLibra OS. The company, focused on RNA interference (RNAi) medicines, is advancing toward its first Clinical Trial Application (CTA) submission in Q4 2025.
The company's pipeline includes TGM-312 for metabolic dysfunction-associated steatohepatitis (MASH) and TGM-148 for bleeding disorders, with the latter planned for regulatory submission in 2026. LLibra OS, built on the foundations of HepNet, combines AI capabilities to identify novel targets, evaluate therapeutic potential, and design GalOmic siRNA medicines.
Tangram Therapeutics (OTC:ETXPF), ex e-therapeutics, ha annunciato un rilancio strategico dell'azienda e ha svelato la sua piattaforma AI di nuova generazione, LLibra OS. L'azienda, focalizzata su farmaci basati su RNA interference (RNAi), sta avanzando verso la presentazione della prima Domanda di Sperimentazione Clinica (CTA) prevista nel Q4 2025.
Il portafoglio comprende TGM-312 per la steatoepatite neuroinfiammatoria associata a disfunzione metabolica (MASH) e TGM-148 per disturbi della coagulazione, con quest'ultimo pianificato per una submission regolatoria nel 2026. LLibra OS, costruita sulle basi di HepNet, combina capacità AI per identificare nuovi bersagli, valutare il potenziale terapeutico e progettare farmaci siRNA GalOmic.
Tangram Therapeutics (OTC:ETXPF), anteriormente e-therapeutics, ha anunciado una relanzación estratégica de la empresa y presentó su plataforma de IA de próxima generación, LLibra OS. La compañía, centrada en fármacos de interferencia de ARN (RNAi), avanza hacia la presentación de su primera Solicitud de Ensayo Clínico (CTA) en Q4 2025.
Su cartera incluye TGM-312 para la esteatohepatitis asociada a disfunción metabólica (MASH) y TGM-148 para trastornos de la coagulación, siendo este último previsto para una presentación regulatoria en 2026. LLibra OS, basada en los fundamentos de HepNet, combina capacidades de IA para identificar nuevos objetivos, evaluar el potencial terapéutico y diseñar fármacos siRNA GalOmic.
Tangram Therapeutics (OTC:ETXPF), 이전에 e-therapeutics였으며, 전략적 기업 재출범을 발표하고 차세대 AI 플랫폼 LLibra OS를 공개했습니다. RNA 간섭(RNAi) 약물에 집중하는 이 회사는 Q4 2025에 첫 임상시험계획서(CTA) 제출을 향해 나아가고 있습니다.
파이프라인에는 대사 기능 장애와 관련된 지방간염(MASH)을 위한 TGM-312와 출혈 장애를 위한 TGM-148이 포함되며, 후자는 2026년 규제 제출을 계획하고 있습니다. HepNet의 기초 위에 구축된 LLibra OS는 신약 타깃 식별, 치료 잠재력 평가 및 GalOmic siRNA 약물 설계를 위해 AI 기능을 결합합니다.
Tangram Therapeutics (OTC:ETXPF), anciennement e-therapeutics, a annoncé une relance stratégique de l’entreprise et dévoilé sa plateforme d’IA de nouvelle génération, LLibra OS. Spécialisée dans les médicaments à base d’interférences ARN (RNAi), la société progresse vers la soumission de sa première Demande d’Essai Clinique (CTA) en Q4 2025.
Son portefeuille comprend TGM-312 pour la stéatohépatite associée à une dysfonction métabolique (MASH) et TGM-148 pour les troubles de la coagulation, ce dernier devant être soumis pour approbation réglementaire en 2026. LLibra OS, fondé sur les bases d’HepNet, combine des capacités d’IA pour identifier de nouvelles cibles, évaluer le potentiel thérapeutique et concevoir des médicaments siRNA GalOmic.
Tangram Therapeutics (OTC:ETXPF), ehemals e-therapeutics, hat eine strategische Neuausrichtung des Unternehmens angekündigt und seine nächste Generationsplattform AI LLibra OS vorgestellt. Das auf RNA-Interferenz (RNAi) basierende Unternehmen macht Fortschritte bei der Einreichung des ersten Clinical Trial Application (CTA) in Q4 2025.
Das Pipeline-Portfolio umfasst TGM-312 für die metabolisch bedingte Steatohepatitis (MASH) und TGM-148 für Gerinnungsstörungen, wobei Letzteres für eine regulatorische Einreichung im Jahr 2026 vorgesehen ist. LLibra OS, basierend auf den Grundlagen von HepNet, kombiniert KI-Fähigkeiten, um neue Zielstrukturen zu identifizieren, das therapeutische Potenzial zu bewerten und GalOmic-siRNA-Medikamente zu entwerfen.
Tangram Therapeutics (OTC:ETXPF)، سابقًا e-therapeutics، أعلنت عن إعادة إطلاق استراتيجية للشركة وكشفت عن منصتها الذكاء الاصطناعي من الجيل التالي LLibra OS. الشركة، التي تركز على أدوية التدخل عبر الحمض النووي الريبي RNA interference (RNAi)، تتقدم نحو تقديم أول طلب تجربة سريرية (CTA) في الربع الرابع من 2025.
تشمل محفظة الشركة TGM-312 لعسر الأيض المرتبط بالتهاب الكبد الدهني وتصلبه، وTGM-148 لاضطرابات النزف، على أن يُقدَّم الأخير للموافقة التنظيمية في 2026. بناء LLibra OS، المستندة إلى أساس HepNet، تجمع إمكانات الذكاء الاصطناعي لتحديد أهداف جديدة، وتقييم الإمكانات العلاجية، وتصميم أدوية siRNA GalOmic.
Tangram Therapeutics (OTC:ETXPF)，前身为 e-therapeutics，宣布战略性公司重塑并推出下一代 AI 平台 LLibra OS。该公司专注于基于RNA干扰（RNAi）药物，正朝着在 2025年第4季度 提交首个临床试验申请（CTA）迈进。
其管线包括用于代谢功能障碍相关脂肪性肝炎（MASH）的 TGM-312，以及用于出血性疾病的 TGM-148，后者计划在 2026 年提交监管申请。LLibra OS 基于 HepNet 的基础，整合 AI 能力以识别新靶点、评估治疗潜力并设计 GalOmic siRNA 药物。
- None.
- No clinical-stage products yet in development
- Regulatory approvals still pending for both pipeline candidates
Relaunch marks pivotal next step in the company’s growth, in anticipation of first CTA submission in Q4 2025.
Introducing LLibra OS, a next-generation AI platform that accelerates discovery and evaluation of differentiated gene targets and siRNA design.
LONDON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Tangram Therapeutics (formerly e-therapeutics), a company committed to uniting computation and RNAi to make better medicines faster, today announced its corporate relaunch. Tangram Therapeutics is inspired by a geometric puzzle, in which differently shaped pieces can be arranged in countless ways to create something greater. Similarly, the Company brings together biological insights, AI, proprietary chemistry, and its people in a focused effort to accelerate the discovery and development of innovative RNAi medicines that transform lives.
Today’s relaunch reflects the progress made since the Company’s pivot to RNA interference medicines. Since then, Tangram Therapeutics has advanced a broad therapeutic pipeline of differentiated GalOmic medicines, powered by its proprietary computational and data-driven approaches. The Company’s lead program, TGM-312 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), is rapidly advancing toward a CTA submission in Q4 2025. As part of its broader pipeline, Tangram is also progressing TGM-148 for the treatment of bleeding disorders through IND-enabling studies, with a regulatory submission for clinical entry planned during 2026. Tangram’s pipeline of first-in-class RNAi medicines highlights both the power of its GalOmic chemistry platform and its ability to discover differentiated therapeutic approaches.
In addition to its relaunch, the Company has unveiled LLibra OS, its next-generation applied AI platform with a modular, multi-agent infrastructure that can continually evolve with the latest advances in AI. LLibra OS is built on the foundations of Tangram’s precursor computational platform HepNet, which was anchored on proprietary network analytics applied to model human disease biology. LLibra OS unifies insights from disparate datasets and proprietary analytical capabilities to enable the identification of novel targets, the evaluation of their therapeutic potential and developability, and the predictive design of GalOmic siRNA medicines. LLibra OS’s co-scientist functionality also supports Tangram’s scientific teams more broadly to increase efficiency and innovation across all research and development activities.
By evolving its proven computational expertise into a more autonomous and integrated AI system, Tangram Therapeutics aims to make smarter decisions earlier in development, to systematically reduce risk and accelerate development of its GalOmic medicines. This advancement reflects the Company’s broader transformation into a data-driven RNAi leader, uniting advanced AI with proprietary chemistry to deliver differentiated medicines.
“Our relaunch today as Tangram Therapeutics represents far more than a new name,” said Ali Mortazavi, Chief Executive Officer of Tangram Therapeutics. “It reflects the company we have become — one that unites proven expertise in AI, biology, and chemistry with a clear focus on developing RNAi medicines. By combining these elements, we are better equipped to identify targets, design effective medicines, and accelerate their path to patients. This bold strategy allows us to diverge from the crowded therapeutic hypotheses being extensively pursued in biopharma and offer differentiated options to patients and carers.”
“Like the eponymous puzzle, Tangram Therapeutics is about connection, perspective, and innovation,” added Alan Whitmore, Chief Scientific Officer. “This extends to LLibra OS, which enables us to make non-obvious connections between diverse pieces of information across widely disparate domains, to identify and evaluate novel targets. This approach ensures that the first-on-target and first-in-class programs in our pipeline are backed by robust evidence and de-risked ahead of development.”
About Tangram Therapeutics
Tangram Therapeutics (formerly e-therapeutics) is a biotech company committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster. We are advancing a pipeline of GalOmic RNAi medicines for a broad range of diseases with high unmet need. Our lead programs TGM-312 for MASH and TGM-148 for bleeding disorders are approaching the clinic, on track for regulatory submissions in Q4 2025 and mid-2026, respectively.
Tangram’s innovative medicines are enabled by GalOmic, our proprietary RNAi chemistry platform designed to selectively silence disease-driving genes in hepatocytes. Discovery is powered by LLibra OS, our next-generation AI platform with an agentic infrastructure. The unique combination of these platforms is the foundation of our Relentless Medicine Discovery. Faster, smarter development of RNAi medicines designed for real-world impact.
Learn more at www.tangramtx.com.
Media Contact
press@tangramtx.com
Investor Relations Contact
IR@tangramtx.com
FAQ
What is the new name of e-therapeutics and why did they change it?
What is Tangram Therapeutics' (ETXPF) lead drug candidate and when will it enter clinical trials?
What is LLibra OS and how does it benefit Tangram Therapeutics?
When will Tangram's TGM-148 for bleeding disorders enter clinical trials?
What therapeutic areas does Tangram Therapeutics (ETXPF) focus on?
